tbuckley/cabot-search huggingface dataset:
Abstract 6167: Appropriate Timing Enhances the Utility of Plasma Brain Natriuretic Peptide in Predicting Survival in Pulmonary Arterial Hypertension
Authors: Omar Batal, Richard A Krasuski, Raed A Dweik
Journal: Circulation (2008)

Background: The natural course of pulmonary arterial hypertension (PAH) is characterized by progressive functional worsening leading to right heart failure and death. Since plasma brain natriuretic peptide (BNP) levels correlate with right ventricular dysfunction, we sought to evaluate the use of BNP as a prognostic indicator in PAH. Methods and Results: We examined our prospective pulmonary hypertension registry for patients who underwent right heart catheterization (RHC) between 1998 and 2008. The BNP values from the time of catheterization until date of last visit or death were analyzed in relationship to overall survival. Of the 626 patients who underwent RHC, 559 met the Venice classification of PAH: 83% category I, 10% category III, 5% category IV, and 2 % category V. Baseline mean pulmonary artery pressures were 47±16 mm Hg and cardiac index 2.6±1 l/min/m 2 . During follow up, patients were treated with prostanoids (27%), endothelin blockers (31%), PDE5 inhibitors (40%), calcium channel blockers (2%), and 56% received combination therapy. BNP values during the first 6 months were higher in patients who died in the first 2 years (n=108) compared to patients surviving more than 5 years (n=82) but the levels had no correlation to survival [R 2 =0.03, p=0.2]. Interestingly, the strongest predictor for survival was the BNP level obtained 12–14 months from RHC [R 2 =0.7, p=0.0001]. All patients who survived over 5 years had BNP value less than 150 ng/L at 12 months and all patients with BNP values &gt;330 ng/L at 12 months were dead by 2 years. Furthermore, there was an accelerated rate of increase in BNP levels in patients who did not survive past 2 years [BNP rise rate (ng/L/month): non- survivors 33 ± 14 while, long-term survivors 0.3 ± 1; p=0.008]. Conclusions: In patients with pulmonary arterial hypertension, initial BNP levels do not appear to have prognostic significance. BNP levels at 1 year, however, are strong predictors of early mortality or long term survival. The rate of rise in BNP levels is a novel concept that may be a useful management tool before the 1 year time point.
Many subjects in trial were not asked for consent
Authors: H. Thornton
Journal: BMJ (1996)

In the UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening, only one out of the nine breast screening centres that took part sought informed consent before randomisation from the 40 163 women attending their first breast screening examination who participated in this trial.1 The remainder sought consent after randomisation and …
Cardiomyogenesis in the Adult Heart
Authors: Annarosa Leri
Journal: Circulation (2013)

In recent years, a novel conceptual view has emerged; the heart is no longer considered a post-mitotic organ, but is viewed as an organ permissive for tissue regeneration mediated by exogenous and/or endogenous progenitor cells. One of the major biological controversies of the last decade has involved the plasticity of c-kit-positive bone marrow cells and their ability to acquire cell lineages different from the organ of origin. The possibility that c-kit-positive bone marrow cells can form cardiomyocytes and coronary vessels repairing the injured heart experimentally was accepted with great enthusiasm by cardiologists, resulting in the clinical implementation of bone marrow mononuclear cells in patients with acute and chronic ischemic cardiomyopathy. A series of negative animal studies, however, has challenged the concept of bone marrow cell transdifferentiation. Conflicting results may be attributed to several factors, including differences in the protocol of cell isolation and administration, animal model of cardiac injury, and methodologies employed for the characterization of the restored cardiac tissue. Importantly, these technical variables cannot account entirely for the reported failure of c-kit-positive bone marrow cells to form de novo myocardium after infarction. The molecular and functional heterogeneity commonly observed in hematopoietic stem/progenitor cells imposes the use of clonal assays for the characterization of c-kit-positive bone marrow cells at the single cell level. Population-based analyses of stem cell behavior fall short in the recognition of the mechanisms of replication and commitment that are unique to distinct progenitor cell subsets. Based on this approach, a restricted class of cardiopoietic c-kit-positive bone marrow cells with a specific molecular signature has been identified. These hematopoietic progenitors transdifferentiate into cardiomyocytes, resistance arterioles and capillaries, repairing the infarcted mouse heart. In contrast, the majority of c-kit-positive bone marrow cells retain their hematopoietic fate in vivo and form only occasionally scattered vascular structures. These findings offer a novel understanding of the long-term controversy on the plasticity and therapeutic efficacy of c-kit-positive bone marrow cells
Cardiovascular Magnetic Resonance Perfusion Imaging at 3-Tesla for the Detection of Coronary Artery Disease
Authors: Adrian S.H. Cheng, Tammy J. Pegg, Theodoros D. Karamitsos, Nick Searle, Michael Jerosch-Herold, Robin P. Choudhury, Adrian P. Banning, Stefan Neubauer, Matthew D. Robson, Joseph B. Selvanayagam
Journal: Journal of the American College of Cardiology (2007)
Prediction of Relapse By microRNA Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia
Authors: Isaac Yaniv, Asaf Lebel, Keren Shichrur, Oshrit Kordi, Anat Ohali, Michal Hameiri-Grossman, Iedan RN Verly, Gertjan JL Kaspers, Jacqueline Cloos, Eva Fronkova, Jan Trka, Drorit Luria, Yona Kodman, Hadar Mirsky, Dafna Gaash, Marta Jeison, Galia Avrahami, Sarah Elitzur, Gil Gilad, Batia Stark, Smadar Avigad
Journal: Blood (2014)
胸水黏附分子CD44、糖原15-3和19-9对良恶性胸腔积液的鉴别诊断价值
Authors: 陈绍平, 刘力兴, 陈小兵, 张国元
Journal: BMJ (2011)

胸膜活检、胸水细胞学及生化检查是胸腔积液病因诊断的常用方法[1].已有大量关于恶性胸腔积液中肿瘤标记物的研究报道,但其中许多研究样本量较小或仅分析单个标记物.本研究通过对2006年1月至2008年2月在我院呼吸科住院治疗的126例胸腔积液患者胸水中的黏附分子CD44、糖原15-3(CA15-3)和CA19-9进行测定,探讨上述3个肿瘤标记物对良恶性胸腔积液的鉴别诊断价值。
Pharmacokinetics, metabolism, and routes of excretion of intravenous [14C]-irofulven in patients with advanced solid tumors
Authors: Francois Lokiec, Kevin Rezai, Pierre Bourgeois, G. Ghanem, G. Vassal, A. Desroussent, Carmen Kahatt, Ajit K. Shah, Dominique De Valeriola
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

3986 

Irofulven is a semi-synthetic derivative of the mushroom derived natural product illudin S that has demonstrated preclinical and clinical activity in a variety of tumor types. Pharmacokinetics, metabolism, and routes of excretion of [14C]-irofulven were evaluated in patients with advanced solid tumors. In this Phase I open label study, 3 patients (2 males and 1 female, 48-64 yr) received a dose of 0.55 mg/kg irofulven containing 100 μCi of [14C]-irofulven administered over a 30 min intravenous infusion on Day 1 of Cycle 1. Serial blood, plasma, urine, fecal, saliva, respiratory air, and tear samples were obtained up to 144 hr after the start of infusion. The plasma radioactivity declined with a distribution phase followed by a long elimination and was measurable up to 144 hr. In plasma, parent irofulven represented 0.2% of total radioactivity AUC(0-t). The Cmax (mean±SD) was 1130 ± 174 ng-eq/ml and 82.7±46.0 ng/ml for radioactivity and parent irofulven, respectively and occurred at Tmax of 0.72±0.12 and 0.29±0.1 hr, respectively. AUC(0-∞), CLp, Vdss, and t½ for irofulven were 65.5±2.39 ng•hr/ml, 8.48±0.14 L/hr/kg, 3.12±1.99 L/kg, and 18±6 min, respectively. Blood to plasma AUC(0-t) ratio of radioactivity was 1.6±0.74 indicating little partitioning of irofulven-derived radioactivity into erythrocytes. Urinary excretion (71.2±9.6% of dose) was a major route of elimination of [14C]-irofulven equivalents and 2.9±2.4% of the radioactive dose was recovered in feces. Low levels of radioactivity were measurable in expired air and saliva. Metabolite profiling of urine samples indicated the presence of irofulven and seven metabolic products and two glucuronide conjugates. Plasma radioactivity profiling showed presence of two metabolites, none representing a major metabolite. The safety profile of irofulven was consistent with previous studies. No grade 4 hematotoxicity or biochemical abnormalities occurred. One patient experienced simultaneous grade 4 vomiting and dehydration (one episode of each). These results indicate that irofulven undergoes extensive metabolism and urinary excretion is the principal route of elimination of metabolites from the body.
Abstract 15116: The Incidence of Severe Bacterial Infections in Asplenia and Polysplenia Syndrome: A Multi-Center Study
Authors: Kouji Sonoda, Shiro Ishikawa, Katsuhiko Mori, Hitomi Boku, Takayuki Yamagishi, Kunitaka Joh-o, Hitoshi Kato, Hiromichi Nakajima, Masaru Miura, Hiroyuki Matsuura, Satoshi Yasukouchi, Seiyou Yasui, Shunichi Ogawa, Kotarou Oyama, Fukiko Ichida, Rumiko Matsuoka, Yoshiyuki Furutani, Toshio Nakanishi
Journal: Circulation (2011)

Backgrounds: Surgical splenecomy is known to increase the risk of bacterial infections (BI). However, the rate of BI in heterotaxy syndrome (congenital asplenia and polysplenia) has not been studie...
Abstract 526: Organic Anion Transporting Peptide 2B1, a High Affinity Transporter for Atorvastatin, is Expressed in Plasma Membranes of Human Platelets, Indicating a Role in Drug Uptake
Authors: Juliane Niessen, Gabriele Jedlitschky, Markus Grube, Sandra Bien, Dieter Rosskopf, Andreas Greinacher, Heyo K Kroemer
Journal: Circulation (2008)

Background & Aim: Effects of statins other than low-density lipoprotein lowering effects include reduced platelet aggregation, which requires drug uptake into platelets. Possible candidates for tra...
Abstract 15006: Transmural Infarct Distribution in Reperfused Myocardium after STEMI
Authors: Thomas M Helle-Valle, Hans-Jorgen Smith, Einar Hopp, Ketil Lunde, Vartdal Trond, Ola Gjesdal, Thor Edvardsen, Otto A Smiseth
Journal: Circulation (2011)

Background: The conventional distinction between transmural and non-transmural infarcts has been challenged by reports of irregular morphology of reperfused myocardium. This study investigates the ...
Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.
Authors: P. Gargiullo, D. Shay, J. Katz, A. Bramley, M. Nowell, J. Michalove, L. Kamimoto, J. A. Singleton, P. J. Lu, L. Balluz, A. Siston
Journal: MMWR Morbidity and Mortality Weekly Report (2009)
Evaluation of the Hemodynamic Performance of Aortic Bioprostheses by Multidetector Computed Tomography. A Feasibilty and Reproducibility Study
Authors: Fabien Chenot, Agnes Pasquet, Bernhard Gerber, Jean-Louis Vanoverschelde, Patrick Montant, Céline Goffinet, David Vancraeynest
Journal: Circulation (2008)
Abstract 19104: Efficacy and Safety of Celecoxib in Patients With Drug-Eluting Stents Implantation: Volumetric Intravascular Ultrasound Analysis
Authors: Il-Young Oh, Ji-Hyun Kim, Jung-Won Suh, Kyung-Woo Park, Hae-Young Lee, Hyun-Jae Kang, Tae-Jin Youn, Bon-Kwon Koo, Dong-Ju Choi, Hyo-Soo Kim, Byung-Hee Oh, Young-Bae Park
Journal: Circulation (2010)

Background: The Celecoxib on Restenosis after Coronary Intervention and Evolution of Atherosclerosis (mini-COREA) trial is a randomized, prospective, multicenter study to evaluate the effects of celecoxib on restenosis after drug-eluting stents (DES) implantation. The aim of this study was to evaluate the effects of celecoxib on neointima formation and late incomplete stent apposition using serial volumetric intravascular ultrasound (IVUS). Methods: In the mini-COREA trial, patients were randomized into control or celecoxib group after DES implantation (paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES)). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the revascularization. Complete serial volumetric IVUS analysis (after DES implantation and at six-month follow-up) was available in 148 patients, including 74 celecoxib patients and 74 controls. Results: No baseline differences were present in the clinical characteristics or baseline IVUS parameters betwe...
Abstract P169: Intensive Nutrigenomic-based Dietary and Supplement Management of Coronary Artery Disease Utilizing Quarterly Measured Advanced Cardiovascular and Genetic Risk Markers: Ten Year Followup
Authors: Steven R Gundry, Jean Epstein
Journal: Circulation (2013)

Introduction: Coronary Artery Disease (CAD) is thought to be progressive; standard treatment protocols call for instituting/instructing a low fat/low cholesterol diet program, exercise, and lipid l...
Abstract 13910: The Impact of Peripheral Arterial Disease on Early Outcome After Transcatheter Aortic Valve Implantation. Results From the German TAVI Registry.
Authors: Jan M Sinning, Martin Horack, Eberhard Grube, Ulrich Gerckens, Raimund Erbel, Holger Eggebrecht, Ralf Zahn, Axel Linke, Horst Sievert, Hans R Figulla, Karl H Kuck, Karl E Hauptmann, Ellen Hoffmann, Rainer Hambrecht, Gert Richardt, Stefan Sack, Jochen Senges, Georg Nickenig, Nikos Werner
Journal: Circulation (2011)

Objective: To determine the impact of peripheral arterial disease (PAD) on clinical outcome after transcatheter aortic valve implantation (TAVI). Background: A significant proportion of patients undergoing TAVI suffers from concomitant PAD which plays a crucial role in the patient selection process and may be associated with worse outcome. Methods: In the prospective, multi-center German TAVI registry, TAVI was performed in 1383 patients with a mean age of 81.7±6.2 years and a logistic Eu-roSCORE of 20.5±13.6%. Results: PAD patients (21.5%) had a higher logistic EuroSCORE (28.5±16.1% vs. 18.3±11.9%; P<0.0001), suffered more often from concomitant comorbidities. After TAVI, the rate of dialysis-dependent renal failure (11.1% vs. 5.5%; P<0.001), vascular complications (27.6% vs. 20.3%; P<0.01), and in-hospital mortality (13.1% vs. 7.0%; P<0.001) was increased in PAD compared to non-PAD patients. For surgical TAVI patients with trans-apical, trans-subclavian, or trans-aortic access, in-hospital mortality rat...
Calculating dose intensity.
Authors: A J Coldman, C M Coppin
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.9.1713 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1875226 Calculating dose intensity. A J ColdmanxA J ColdmanSearch for articles by this author , C M CoppinxC M CoppinSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.9.1713 PDF "Calculating dose intensity.." Journal of Clinical Oncology, 9(9), pp. 1713–1714© 1991 by American Society of Clinical Oncology
Abstract 9462: Plaque Characteristics on Computed Tomography Coronary Angiography Which Developed Acute Coronary Syndrome More Than One Month Later
Authors: Shinichiro Fujimoto, Takeshi Kondo, Takahide Kodama, Tadaaki Orihara, Junichi Sugiyama, Makoto Kondo, Akira Endo, Hiroshi Fukazawa, Hideki Nagaoka, Akitsugu Oida, Shinichi Takase
Journal: Circulation (2011)

Backgrounds: 64 or 320-slice CTCA were undergone in 8777 consecutive patients at our center for evaluation of coronary artery disease (CAD) (known CAD: 2319). Of 8777, 27 (M/F=25/2, 67±10 yrs, period to ACS onset: 541±500 days, known CAD: 15) patients developed ACS after having passed more than 30 days from CTCA examination (Patients of culprit lesions which were stent site were excluded.). We examined the culprit plaque characteristics of on CTCA for ACS in the 27 patients. Methods: 64 or 320-slice CTCA were undergone in 8777 consecutive patients at our center for evaluation of coronary artery disease (CAD) (known CAD: 2319). Of 8777, 27 (M/F=25/2, 67±10 yrs, period to ACS onset: 541±500 days, known CAD: 15) patients developed ACS after having passed more than 30 days from CTCA examination (Patients of culprit lesions which were stent site were excluded.). We examined the culprit plaque characteristics of on CTCA for ACS in the 27 patients. Results: Culprit lesions were observed at LMT in 2, RCA in 9, LAD in10, LCX in 6 cases. Nineteen cases (70.4%) were observed in the proximal or mid portion of the three major coronary arteries. No significant stenosis (≤50%) were observed in 21 cases (80.8%). Positive remodeling (PR: remodeling index&gt;1.1) were found in 20 (74.1%) and low attenuation plaque (LAP: CT values≤50HU) were found in 14 (51.9%) cases. No calicification was observed in 5, spotty calcification in 8, moderate calcification in 10 and severe calcification in 4 cases. The period to ACS onset tended to be shorter in ≥50% stenosis, and age was significantly younger with PR(+) group. The VPs were classified by CTCA findings into 4 types; Type I(PR(+) and LAP(+)) was observed in 14(52%), Type II(PR(+) and LAP(-)) in 6(22%), Type III(PR(-) and LAP(-)) in 4(15%), and Type IV(PR(-) and severe calcification) in 3(11%) pts. Conclusions: Although ACS occurred from various plaque characters in CTCA, about half of ACS were derived from Type I (PR(+) and LAP(+)) plaques in the younger patients.
Abstract 237: The Effects of Transvenous Pacemaker and Implantable Cardioverter Defibrillator Lead Placement on Tricuspid Regurgitation
Authors: Qiangjun Cai, Mossaab Shuraih, Zaher Fanari, Masood Ahmad, David L Ware, Salvatore Rosanio
Journal: Circulation (2009)

Background : The incidence of new or worsening tricuspid regurgitation (TR) after permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD) lead placement has not been well investigated.   Objective : We compared echocardiograms pre- and post-implantation to determine if PPM or ICD lead placement causes or worsens TR.   Methods and Results : We reviewed the charts of all patients undergoing PPM or ICD lead placement in our electrophysiology laboratory from December 2001 to December 2006. Of these, we compared the severity and frequency of TR before and after lead insertion in 206 patients (120 with PPM and 86 with ICD) who had baseline echocardiography within 6 months before, and a follow up study at least 6 months after lead insertion. The mean age was 74±14 years; 56% were men. The follow-up period was 29±19 months. TR was graded as absent or trace, mild, moderate, or severe. Prior to implant, 34.5%, 45.1%, 16.0%, and 4.4% of patients had absent or trace, mild, moderate, or severe TR. Post-implant, the respective frequencies were 13.6%, 52.9%, 23.8%, and 9.7% (Chi-square 54.6,  P    Conclusion : Our data shows that, the implantation of the transvenous PPM or ICD leads induces and aggravates tricuspid regurgitation.
Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
Authors: Demosthenes G. Katritsis, Evgeny Pokushalov, Alexander Romanov, Eleftherios Giazitzoglou, George C.M. Siontis, Sunny S. Po, A. John Camm, John P.A. Ioannidis
Journal: Journal of the American College of Cardiology (2013)
Abstract 289: The Relationship of Chest Compression Rate and Survival During Out-of-Hospital Cardiopulmonary Resuscitation at Resuscitation Outcomes Consortium (ROC) Regional Sites
Authors: Ahamed H Idris, Danielle Guffey, Paul P Pepe, Mohamud Daya, Dan Davis, Ian G Stiell, James Menegazzi, Clifton Callaway, James Christenson, Randal Gray, Douglas Boyce, Steve Lin, Kellie Sheehan, Tom Aufderheide
Journal: Circulation (2011)

Background: Current American Heart Association guidelines for cardiopulmonary resuscitation (CPR) recommend a chest compression rate of at least 100 compressions/min. Animal and human CPR studies have reported improved blood flow associated with chest compressions rates ≥ 120/min, but few have reported rates used during out-of-hospital (OOH) CPR, or the relationship between rate and outcome. Objective: To describe chest compression rates used by emergency medical services (EMS) providers to resuscitate patients with OOH cardiac arrest and to determine the relationship between rate and outcome. Methods: Included were patients ≥ 20 years old enrolled in the ROC PRIMED study with OOH cardiac arrest treated by EMS providers. Data were abstracted from monitor-defibrillator recordings during the first 5 minutes of CPR. Multiple logistic regression assessed the association between chest compression rate and outcome. The model adjusted for sex, age, bystander and EMS witnessed arrest, attempted bystander CPR, public location, and ROC site. Results: 10,330 patients had OOH CPR from June 2007 to November 2009. Mean age was 67 ± 16. Mean chest compression rate was 111 ± 19 (3 - 210) compressions/min during the first 5 minutes of CPR. Return of spontaneous circulation occurred in 34% and 9% survived to hospital discharge. Compared with the reference rate (100-120/min) (mean 109 ± 6), the adjusted odds ratios (OR) for survival were: compression rate from 0 - 80/min (mean 68 ± 13) OR 1.18 (CI 0.78 - 1.77), 80 - 100/min (mean 93 ± 5) OR 0.88 (0.73 - 1.06), 120 - 140/min (mean 128 ± 5) OR 0.88 (CI 0.73 - 1.08), &gt;140/min (mean 151 ± 11) OR 0.77 (CI 0.54 - 1.11). A cubic spline curve suggests survival peaks at about 120/min and then declines at rates &gt;120/min. Conclusion: Chest compression rates faster than 100/min were common. The study suggests that the likelihood of survival from OOH cardiac arrest is decreased with compression rates &gt;120/min.
Studies on the Exchange of Fluids Between Host and Tumor. II. The Blood Flow of Hepatomas and Other Tumors In Rats and Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Pietro M. Gullino, Flora H. Grantham
Journal: JNCI Journal of the National Cancer Institute (1961)

The blood supply of transplanted tumors was studied by two methods. The first, a direct method, is based on the cannulation of the single vein draining the blood from the neoplasm. The second, an indirect method, is based on the distribution of two indicators, K42 and Rb86, to the tumor. In rats, the blood supply of all tumors studied followed a uniform pattern independent of the histologic type, site of implantation, and size of the neoplasm. The results of both methods were remarkably close. The average value of the blood supply to tumors grown “tissue-isolated” was 0.14 ± 0.01 ml per hour per mg N with the direct method and 0.15 ± 0.01 ml per hour per mg N with the indirect method. The average value of blood supply to subcutaneous transplants was 0.17 ± 0.02 ml per hour per mg N. Therefore, a hepatoma had a blood supply roughly 20-fold smaller than that of the host liver. Livers regenerating after hepatectomy had the same blood supply as normal livers when the values were expressed in ml per hour per mg N. In mice, the blood supply of tumors followed the general pattern found in rats. The total amount of blood flowing through the host organ did not influence the growth rate of the transplanted tumor if the flow reached the required low rate.